TheraRadar

TheraRadar News

FREE · NO SUBSCRIPTION

Every headline opens the original press release, FDA letter or SEC filing ↗ · free, no sign-up

About this feed: sources, ranking and AI summaries

The drug-development news that matters, gathered each day from the primary sources: the FDA, SEC filings and the newsrooms of over 150 drug developers, from big pharma to startups, plus the AI labs working on drug discovery.

  • FDA decisions: new drug and biologic approvals, biosimilars, PDUFA outcomes
  • Trials: Phase 1, 2 and 3 results, trial starts and data at medical meetings
  • Deals: acquisitions, licensing, collaborations (AI partnerships too) and financings
  • Company news: quarterly results, pipeline updates, restructurings

Stories go back to August 19, 2026, and every story is kept. Within each day the most important stories come first: approvals, then Phase 3 results, then big deals. Switch to This week for the top stories in one view, or Headlines for one line per story. Stories added since your last visit are marked New. Routine notices (investor-conference schedules, stock grants, awards) are left out. Short summaries marked AI summary are written from the release itself, and every number in them is checked against it. An AI model also tags each story's disease area for the filter, and leaves it blank when a story spans many areas. Revenue bars on results stories show the figures the company states, each checked against its release. Past weeks are also kept as pages in the weekly archive.

View
More filters
Coming up

FDA decision dates

  1. Nov 14 Ivonescimab + chemotherapy · Summit Therapeutics Inc.
  2. Nov 14 IGALMI · BioXcel Therapeutics, Inc.
  3. Nov 14 MYQORZO (aficamten) · Cytokinetics, Incorporated
  4. Nov 22 MOLBREEVI (molgramostim) inhalation solution · Savara Inc.
  5. Nov 22 Deramiocel (CAP-1002) · Capricor Therapeutics, Inc.
  6. Nov 27 BBP-418 (ribitol) · BridgeBio Pharma, Inc.
  7. Nov 27 Neladalkib (NVL-655) · Nuvalent, Inc.
  8. Nov 28 D-PLEX100 · PolyPid Ltd.
  9. Nov 30 Povetacicept (ALPN-303) · Vertex Pharmaceuticals Incorporated
  10. Nov 30 Giredestrant · Genentech, Inc. (Roche)
  11. Nov 30 Bezuclastinib + sunitinib · Cogent Biosciences, Inc.
  12. Dec 3 Zanzalintinib (XL-092) + atezolizumab · Exelixis, Inc.
Full PDUFA calendar →

Medical meetings

  1. Nov 12 – 15 SNO
  2. Nov 14 – 17 ObesityWeek
  3. Nov 16 – 19 CTAD
  4. Nov 18 – 20 EORTC-NCI-AACR
  5. Dec 4 – 8 AES
  6. Dec 4 – 6 ESMO Asia
  7. Dec 8 – 11 SABCS
  8. Dec 12 – 15 ASH
  9. Jan 11 – 14 JPM
All conferences →

Loading news…

Free to read and free to share. Sources: FDA approval records and letters, human-confirmed PDUFA outcomes, SEC EDGAR filings, and companies' own press-release feeds. Company headlines are shown as published; an AI model (Gemini) sorts releases (keeps news, drops routine notices), tags the trial phase only when the release states it, and writes the short summaries marked AI summary, whose numbers are checked against the release.

Past weeks: weekly archive. Follow in a feed reader: RSS feed. See something wrong or missing? Tell us.